Hepcidin as a Predictor of Response to Epoetin Therapy in Anemic Cancer Patients
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Background: Hepcidin is thought to be the central regulator of iron metabolism. Iron deficiency is associated with low hepcidin concentrations, and anemia in patients with cancer is associated with high concentrations of hepcidin. Study objectives: Our main objective was to assess the potential role of hepcidin for predicting response to epoetin therapy in anemic cancer patients. We also aimed to identify a cutoff value for hepcidin as a potential predictive marker for response to epoetin therapy. Methods: Using data from 525 anemic cancer patients enrolled in 5 studies, we assessed serum hepcidin concentrations in 408 of these patients at baseline and analyzed pooled data from the 408 patients. The analysis population was separated into 2 categories using a threshold hepcidin concentration of 13 nmol/L: low hepcidin (<13 nmol/L) and high hepcidin (≥13 nmol/L). Results: A significantly higher percentage of responders (defined as hemoglobin increase ≥10 g/L or ≥20 g/L from baseline) was observed in the low hepcidin group compared with the high hepcidin group (P = 0.04 for ≥10 g/L increase and P = 0.009 for ≥20 g/L from baseline). There was also a statistically significant difference between the 2 groups for hematopoietic response (hemoglobin rise at least once ≥20 g/L from baseline or at least once ≥120 g/L) to epoetin therapy (P = 0.0004). Conclusions: The results of this analysis suggest a potential role of hepcidin serum concentrations in predicting the response to epoetin therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hepcidin, a urinary antimicrobial peptide synthesized in the liver
Park, C. H., Valore, E. V., Waring, A. J., & Ganz, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008922200 · Cited by 2,168 · cited 2×
“The exons encode an 84–amino acid prepropeptide containing a typical 24–amino acid leader peptide at the N-terminus, a 35–amino acid proregion, and the C-terminal 20– or 25–amino acid peptide (1).”
BackgroundPigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
Nemeth, E., Valore, E. V., Territo, M., Schiller, G., Lichtenstein, A., & Ganz, T. (2003) · Blood · doi:10.1182/blood-2002-10-3235 · Cited by 1,417 · cited 4×
“…part of this hypore-sponsiveness to epoetin therapy in cancer patients is thought to be caused by the decreased availability of iron for the synthesis of hemoglobin during inflammatory stages, because the use of endogenous iron and the iron absorption is blocked by upregulated hepcidin (9, 10) .”
BackgroundInfluentialNicolas, G., Bennoun, M., Devaux, I., Beaumont, C., Grandchamp, B., Kahn, A., & Vaulont, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151179498 · Cited by 1,233
Interleukin‐6 and its receptor in cancer: Implications for Translational Therapeutics
Hong, D. S., Angelo, L. S., & Kurzrock, R. (2007) · Cancer · doi:10.1002/cncr.22999 · Cited by 370
Iron and inflammation: cross-talk between pathways regulating hepcidin
Fleming, R. E. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0349-8 · Cited by 54
Cited by
Hepcidin in Human Iron Disorders: Diagnostic Implications
Kroot, J. J., Tjalsma, H., Fleming, R. E., & Swinkels, D. W. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2009.140053 · Cited by 246
A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates
Cooke, K. S., Hinkle, B., Salimi-Moosavi, H., Foltz, I., King, C., Rathanaswami, P., Winters, A., Steavenson, S., Begley, C. G., Molineux, G., et al. (2013) · Blood · doi:10.1182/blood-2013-06-505792 · Cited by 113
Anemia in Hodgkin's Lymphoma: The Role of Interleukin-6 and Hepcidin
Hohaus, S., Massini, G., Giachelia, M., Vannata, B., Bozzoli, V., Cuccaro, A., D'Alo', F., Larocca, L. M., Raymakers, R. A. P., Swinkels, D. W., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6873 · Cited by 110
Diagnosis of iron-deficient states
Archer, N. M., & Brugnara, C. (2015) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1038744 · Cited by 82
van Eijk, L. T., Kroot, J. J., Tromp, M., van der Hoeven, J. G., Swinkels, D. W., & Pickkers, P. (2011) · Critical Care · doi:10.1186/cc9408 · Cited by 48
“The association of increased concentrations of hepcidin with anemia has been determined in patients suffering from chronic inflammation [8], chronic kidney disease [9], and cancer [10].”
Background
Metadata
- Authors
- Ukarma, L., Johannes, H., Beyer, U., Zaug, M., Osterwalder, B., & Scherhag, A.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-01
- Volume
- 55
- Issue
- 7
- Pages
- 1354-1360
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2133612580
- Cited by
- 29
- References
- 6
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.